Biotech | August 05, 2021
Novavax signs agreement with European Commission for COVID19 vaccine
Deal for 100 million doses with additional 100 million through 2023
Deal for 100 million doses with additional 100 million through 2023
It is part of the company’s pain/analgesics portfolio of OTC products
The govt has rolled out three schemes for promoting the manufacture of API
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company posted net profit of Rs.89.20 crores for the period ended June 30, 2020.
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Subscribe To Our Newsletter & Stay Updated
